Saturna Capital CORP lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,068,102 shares of the company’s stock after buying an additional 2,118 shares during the quarter. Novo Nordisk A/S comprises approximately 1.7% of Saturna Capital CORP’s investment portfolio, making the stock its 21st biggest holding. Saturna Capital CORP’s holdings in Novo Nordisk A/S were worth $51,429,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC boosted its stake in Novo Nordisk A/S by 6.1% during the 2nd quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock worth $111,000 after acquiring an additional 150 shares during the last quarter. AlphaMark Advisors LLC boosted its stake in Novo Nordisk A/S by 1.1% during the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after acquiring an additional 30 shares during the last quarter. MUFG Americas Holdings Corp boosted its stake in Novo Nordisk A/S by 100.0% during the 2nd quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock worth $129,000 after acquiring an additional 1,500 shares during the last quarter. Parallel Advisors LLC boosted its stake in Novo Nordisk A/S by 44.4% during the 2nd quarter. Parallel Advisors LLC now owns 4,108 shares of the company’s stock worth $174,000 after acquiring an additional 1,264 shares during the last quarter. Finally, First National Trust Co. bought a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $218,000. 6.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of Novo Nordisk A/S (NVO) traded down $0.34 on Wednesday, reaching $50.70. 1,923,400 shares of the company’s stock were exchanged, compared to its average volume of 2,098,203. Novo Nordisk A/S has a 1 year low of $32.83 and a 1 year high of $52.32. The company has a market capitalization of $130,152.00, a price-to-earnings ratio of 22.29, a P/E/G ratio of 3.05 and a beta of 0.63.
A number of brokerages have weighed in on NVO. BidaskClub raised shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Bank of America raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, September 6th. Zacks Investment Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Wednesday, September 13th. BNP Paribas lowered shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $55.00.
ILLEGAL ACTIVITY NOTICE: “Saturna Capital CORP Has $51.43 Million Stake in Novo Nordisk A/S (NVO)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/06/saturna-capital-corp-has-51-43-million-stake-in-novo-nordisk-as-nvo.html.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.